Bial Trial Tragedy: No Safety Clue From Similar Products
This article was originally published in Scrip
Though officially unconfirmed, it is presumed that the fatty acid amide hydrolase inhibitor at the center of the Bial clinical trial disaster is BIA 10-2474, which was in Phase I development for the treatment of "neurological and psychiatric pathologies". But there were few clues to its potential toxicity from previous products with this mechanism of action investigated, and dropped from development.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.